These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31306749)

  • 1. Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations.
    Dahlgren D; Sjöblom M; Lennernäs H
    Eur J Pharm Biopharm; 2019 Sep; 142():411-420. PubMed ID: 31306749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions.
    Roos C; Dahlgren D; Sjögren E; Sjöblom M; Hedeland M; Lennernäs H
    Eur J Pharm Biopharm; 2019 Sep; 142():387-395. PubMed ID: 31306752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs.
    Dahlgren D; Roos C; Johansson P; Tannergren C; Lundqvist A; Langguth P; Sjöblom M; Sjögren E; Lennernäs H
    Int J Pharm; 2018 Aug; 547(1-2):158-168. PubMed ID: 29758344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport.
    Dahlgren D; Roos C; Lundqvist A; Tannergren C; Sjöblom M; Sjögren E; Lennernäs H
    Int J Pharm; 2018 Oct; 549(1-2):239-248. PubMed ID: 30055302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-dependent effects on small intestinal transport by absorption-modifying excipients.
    Dahlgren D; Roos C; Lundqvist A; Tannergren C; Sjöblom M; Sjögren E; Lennernäs H
    Eur J Pharm Biopharm; 2018 Nov; 132():19-28. PubMed ID: 30179738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker
    Dahlgren D; Roos C; Lundqvist A; Tannergren C; Langguth P; Sjöblom M; Sjögren E; Lennernäs H
    Mol Pharm; 2017 Dec; 14(12):4243-4251. PubMed ID: 28737406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs.
    Flanagan T
    Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral absorption enhancement: taking the next steps in therapeutic delivery.
    Brayden DJ; Maher S
    Ther Deliv; 2010 Jul; 1(1):5-9. PubMed ID: 22816114
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
    Chen ML
    Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of excipient interactions on drug bioavailability from solid dosage forms.
    Panakanti R; Narang AS
    Pharm Res; 2012 Oct; 29(10):2639-59. PubMed ID: 22610283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism.
    Mudra DR; Borchardt RT
    J Pharm Sci; 2010 Feb; 99(2):1016-27. PubMed ID: 19650119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of excipients on transporter mediated absorption.
    Goole J; Lindley DJ; Roth W; Carl SM; Amighi K; Kauffmann JM; Knipp GT
    Int J Pharm; 2010 Jun; 393(1-2):17-31. PubMed ID: 20417699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence.
    García-Arieta A
    Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Pharmaceutical Excipients on Intestinal Absorption of Metformin via Organic Cation-Selective Transporters.
    Ruan Y; Li X; You L; Chen J; Shen Y; Zhang J; Yuan Y; Kang L; Qin C; Wu C
    Mol Pharm; 2021 Jun; 18(6):2198-2207. PubMed ID: 33956455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Absorption Promoters: Opportunities, Issues, and Challenges.
    Yewale C; Patil S; Kolate A; Kore G; Misra A
    Crit Rev Ther Drug Carrier Syst; 2015; 32(5):363-87. PubMed ID: 26559432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
    Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM
    Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis.
    Avdeef A; Kansy M; Bendels S; Tsinman K
    Eur J Pharm Sci; 2008 Jan; 33(1):29-41. PubMed ID: 17983735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.
    Lo YL
    J Control Release; 2003 Jun; 90(1):37-48. PubMed ID: 12767705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspective on improving passive human intestinal absorption.
    Yalkowsky SH
    J Pharm Sci; 2012 Sep; 101(9):3047-50. PubMed ID: 22374839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.